A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Bortezomib; Dexamethasone; Doxorubicin
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PIMMS
- 10 Jun 2017 Biomarkers information updated
- 16 May 2012 Actual patient number changed from 108 to 107 as reported by ClinicalTrials.gov.
- 16 May 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.